The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Current Opinion in Pharmacology · 2024
DOI: 10.1016/j.coph.2024.102448 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Opinion in Pharmacology, 2024. Verfasst von Heping Xu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Changsha Aier Eye Hospital, Changsha, Hunan, China; Aier Eye Institute, Aier Academy of Ophthalmology, Central South University, Hunan, China; The We…. Hauptthemen laut MEDLINE: Macular Degeneration, Fibrosis, Complement System Proteins. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fight for Sight UK, Natural Science Foundation of Hunan Province, UKRI Medical Research Council.
Abstract (Originalsprache)
Neovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no medication to prevent or treat the condition. Here, we discussed recent advances in the pathogenesis of nAMD-mediated macular fibrosis, with a focus on the role of the complement system. We further proposed approaches to target the complement system for the management of macular fibrosis and highlighted the area of further research for future clinical applications of complement-based therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Changsha Aier Eye Hospital, Changsha, Hunan, China; Aier Eye Institute, Aier Academy of Ophthalmology, Central South University, Hunan, China; The Wellcome-Wolfson Institute for Experimental Medicine, Queen's University…
- Changsha Aier Eye Hospital, Changsha, Hunan, China; Aier Eye Institute, Aier Academy of Ophthalmology, Central South University, Hunan, China; Changsha Xiangjiang Aier Eye Hospital, Changsha, Hunan, China.
- The Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, United Kingdom. Electronic address: m.chen@qub.ac.uk.
Förderung
- Fight for Sight UK
- Natural Science Foundation of Hunan Province
- UKRI Medical Research Council
Zitieren
APA
Xu, H., Yi, C., & Chen, M. (2024). The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis. Current Opinion in Pharmacology. https://doi.org/10.1016/j.coph.2024.102448
Vancouver
Xu H, Yi C, Chen M. The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis. Current Opinion in Pharmacology. 2024. doi:10.1016/j.coph.2024.102448
BibTeX
@article{Xu2024,
author = {Xu, Heping and Yi, Caijiao and Chen, Mei},
title = {The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis},
journal = {Current Opinion in Pharmacology},
year = {2024},
doi = {10.1016/j.coph.2024.102448}
}
EUVIMED